Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s share price hit a new 52-week low during trading on Thursday. The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 2,000 shares. The stock had previously closed at C$0.02.
Quest PharmaTech Price Performance
The company has a 50 day moving average of C$0.02 and a 200-day moving average of C$0.03. The company has a market cap of C$3.38 million, a P/E ratio of 0.68 and a beta of -0.75. The company has a debt-to-equity ratio of 4.35, a current ratio of 0.40 and a quick ratio of 0.52.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Recommended Stories
- Five stocks we like better than Quest PharmaTech
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
- Plugging In: Vertiv Cashes In On AI Demand
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
